New Delhi: With 37,148 fresh COVID-19 positive cases reported in the last 24 hours, India’s tally of coronavirus reached 11,55,191 on Tuesday. The death toll, on the other hand, surpassed the 28,000 mark after 587 people succumbed to the infection. “Total COVID-19 positive cases stand at 11,55,191 including 4,02,529 active cases, 7,24,578 cured/discharged/migrated and 28084 deaths”, the Ministry of Health and Family Welfare said today.
Meanwhile, the trial data of a COVID-19 vaccine developed by AstraZeneca and Oxford University revealed that it is safe and induces immune response, with mild side effects in some participants, which the scientists say can be treated with the commonly available pain medication paracetamol.
The preliminary results of the phase I/II trial, just published in The Lancet journal, involved 1,107 healthy adults, and found that the vaccine induced an immune response both via antibodies and the T cells of the immune system up to day 56 of the ongoing trial.
The Serum Institute of India (SII) will soon apply to the Indian regulator for the licensure trials of the AstraZeneca-Oxford Covid vaccine. Commenting on the AstraZeneca-Oxford vaccine’s results, Adar Poonawalla, CEO, Serum Institute of India, said, “The trials have shown promising results and we are extremely happy about it. We will be applying for the licensure trials to the Indian regulator in a week’s time.
1,43,81,303 samples tested for COVID-19 up to 20th July. Of these 3,33,395 were tested yesterday, said Indian Council of Medical Research (ICMR).